Abstract: The present invention relates to a cellular component homogenate in liquid form, as well as to a cellular component homogenate in solid form, preferably as sprayed powder. Furthermore, the present invention relates to a homogenisation process for the preparation of said cellular component homogenate in liquid form and said cellular component homogenate in solid form, preferably as sprayed powder. Lastly, the present invention relates to a composition comprising said cellular component homogenate in solid form and, optionally, one or more pharmaceutical or food grade or cosmetic additives and excipients, for use in the pharmaceutical, nutraceutical, medical devices, foods for special medical purposes, dietary supplements and food industry both in the human and veterinarian field, as well as for use in the cosmetics industry.

Abstract: A method applying cytofluorometry to a biomass of freeze-dried bacterial cells (freeze-dried biomass) is described. The method is performed for evaluating the stability of said freeze-dried bacterial cells. Methods applying cytofluorometry to preparation of a freeze-dried biomass, and for evaluating the integrity of a cell wall present in freeze-dried bacterial cells are also described.

Abstract: The present invention relates to mixtures, or compositions comprising said mixtures, comprising at least one bacterial strain, preferably at least one probiotic bacterial strain or a derivative thereof, as well as to the use of said mixtures or compositions in methods for the preventive and/or curative treatment of an inflammatory ocular and/or periocular lesion, preferably in methods for the treatment of ocular diseases such as dry eyes, eyelid allergy, conjunctivitis, blepharitis, meibonite, dacryoliths, stye, inflammatory lesions of ocular adnexa and associated symptoms.

Abstract: The present invention relates to a pharmaceutical composition or a composition for a medical device or a composition for a food supplement (briefly, the composition (s) of the present invention) based on lactic acid bacteria belonging to the species Lactobacillus fermentum for vaginal and oral use for the simultaneous treatment of vaginal infections, disorders or diseases of fungal and bacterial origin. Specifically, the present invention relates to a said composition comprising pharmaceutical- and/or food-grade excipients and a mixture, which comprises or, alternatively, consists of at least a strain of bacteria belonging to the species Lactobacillus fermentum for vaginal and oral use for the simultaneous treatment of vaginal infections, disorders or diseases selected from candidiasis, vaginitis, vulvovaginitis or bacterial vaginosis.

Abstract: An isolated strain of bacteria Bifidobacterium breve (B632) DSM 24706 and related mixtures, compositions and methods for treatment of a disorder or an ailment or a disease of the respiratory airways including asthma and dyspnoea are described. The composition comprising the mixture includes at least one physiologically and/or pharmacologically acceptable additive and/or technological excipient. The isolated strain mixture and composition can be administered to paediatric subjects having a disorder or an ailment or a disease of the respiratory airways.

Abstract: The present invention refers to a composition for use in the treatment of sleep disorder, in particular, in the improvement of sleep quality. Furthermore, the present invention refers to a composition for use in the treatment of mood modulation.

Abstract: This invention relates to a composition for use in the treatment of major depressive disorder. In addition, this invention relates to a composition for use in the treatment and/or improvement of mood disturbances and for use in the treatment and/or improvement of the mood state.

Abstract: The present invention refers to a composition for use in the treatment of sleep disorder, in particular, in the improvement of sleep quality. Furthermore, the present invention refers to a composition for use in the treatment of mood modulation.

Abstract: The present invention relates to selected strains of lactic bacteria for use in the treatment of infections caused by pathogenic bacteria belonging to the species Propionibacterium acnes, in particular for use in the preventive and/or curative treatment of dermatitis in general, seborrheic dermatitis, rosacea, eczema and acne. In addition, the present invention relates to a composition which comprises a mixture comprising or, alternatively, consisting of selected strains of lactic bacteria for use in the treatment of infections caused by pathogenic bacteria belonging to the species Propionibacterium acnes, in particular for use in the preventive and/or curative treatment of dermatitis in general, seborrheic dermatitis, rosacea, eczema and acne.

Abstract: The present invention refers to a composition for use in the treatment of sleep disorder, in particular, in the improvement of sleep quality. Furthermore, the present invention refers to a composition for use in the treatment of mood modulation.

Abstract: Selection of probiotic strains belonging to the genus Bifidobacterium and to a symbiotic composition containing the same for use of feeding infants, is described.

Abstract: This invention relates to a composition for use in the treatment of major depressive disorder. In addition, this invention relates to a composition for use in the treatment and/or improvement of mood disturbances and for use in the treatment and/or improvement of the mood state.

Abstract: The present invention relates to a bacterial composition which can be effectively used in the field of sport nutrition, since it is capable of attenuating the decline in sport performance in a subject after a muscle-damaging exercise.

Abstract: The present invention provides anallergic compositions, including food products, comprising probiotic bacterial cultures including probiotic strains of Lactobacillus, Bifidobacterium, Lactococcus, Streptococcus, and/or Staphylococcus.

Abstract: A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis.

Abstract: Selected bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia are described. In particular, a food composition or supplement product or medical device or pharmaceutical composition has said bacterial strains in association with sterols or phytosterols and/or stanols or phytostanols and/or glucomannan and/or konjac gum and/or prebiotic fibres and/or fermented red rice and/or betaglucans from oats, oat bran, barley, barley bran and/or Aloe arborescens gel in lyophilized form.

Abstract: The use of at least one flavonoid of natural or synthetic origin in association with cyclophosphamide and/or methotrexate to increase the effectiveness of chemotherapeutic treatments used in human and veterinary medicine for the treatment of tumors is described, in particular in case of resistance to the chemotherapeutic agents currently in use. At least one flavonoid herein described is selected from the group comprising or, alternatively, consisting of rutin, oxerutin, diosmin, troxerutin and hesperidin.

Abstract: Compositions having at least one flavonoid of natural or synthetic origin in association with melatonin to increase the effectiveness of chemotherapeutic treatments used in human and veterinary medicine for the treatment of tumours are described. The compositions are in particular for the treatment of tumours resistant to the chemotherapeutic agents currently in use. The at least one flavonoid is selected from rutin, oxerutin, diosmin and hesperidin, preferably rutin.

Abstract: A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis.

Abstract: A selection of strains of lactic bacteria and bifidobacteria of human intestinal origin capable of metabolizing oxalates is described. Moreover, a food composition or supplement product or pharmaceutical composition containing said bacterial strains is also described.